<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02364947</url>
  </required_header>
  <id_info>
    <org_study_id>339-14-001</org_study_id>
    <secondary_id>JapicCTI-152804</secondary_id>
    <nct_id>NCT02364947</nct_id>
  </id_info>
  <brief_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy, safety, and dose-response of nalmefene hydrochloride at 10 mg and 20 mg in
      patients with alcohol dependence will be evaluated in a multicenter, randomized,
      double-blind, placebo-controlled, 3-parallel-group comparative trial. The superiority of
      nalmefene hydrochloride at 20 mg to placebo will be verified in terms of reduction of alcohol
      consumption.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 9, 2015</start_date>
  <completion_date type="Actual">July 30, 2016</completion_date>
  <primary_completion_date type="Actual">July 30, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Number of Heavy Drinking Days (HDDs) From Baseline at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The number of HDDs is defined as the number of days per month [days/month] with alcohol consumption of &gt; 60 g for males and &gt; 40 g for females</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Number of Heavy Drinking Days (HDDs) From Baseline at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Alcohol Consumption (TAC) From Baseline at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Alcohol Consumption (TAC) From Baseline at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Shift Drinking Risk Level (RSDRL) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of patients with a downward shift in drinking risk level of two categories or more</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Shift Drinking Risk Level (RSDRL) at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Proportion of patients with a downward shift in drinking risk level of two categories or more</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Low Drinking Risk Level (RLDRL) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of patients with low or lower drinking risk level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Low Drinking Risk Level (RLDRL) at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Proportion of patients with low or lower drinking risk level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>70% TAC Responder Rate at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of patients with a 70% decrease in TAC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>70% TAC Responder Rate at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Proportion of patients with a 70% decrease in TAC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDD Responder Rate at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of patients with ≤4 HDDs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDD Responder Rate at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Proportion of patients with ≤4 HDDs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CGI-S From Baseline at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The CGI-S scale was used by clinicians when assessing their global impression of a patient's current clinical condition. The investigator or subinvestigator used his/her clinical experience with this patient population to rate the severity of a subject's clinical condition on a 7-point scale ranging from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CGI-S From Baseline at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The CGI-S scale was used by clinicians when assessing their global impression of a patient's current clinical condition. The investigator or subinvestigator used his/her clinical experience with this patient population to rate the severity of a subject's clinical condition on a 7-point scale ranging from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CGI-I From Baseline at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The CGI-I scale is used to assess a patient's improvement (or worsening). The investigator or subinvestigator assesses a subject's condition relative to baseline on a 7-point scale ranging from 1 (Very much improved) to 7 (Very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CGI-I From Baseline at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The CGI-I scale was used to assess a patient's improvement (or worsening). The investigator or subinvestigator assesses a subject's condition relative to baseline on a 7-point scale ranging from 1 (Very much improved) to 7 (Very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Logarithm Scale in Serum γ-glutamyltransferase From Baseline at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>All-patients-randomised set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Logarithm Scale in Serum γ-glutamyltransferase From Baseline at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>All-patients-randomised set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Logarithm Scale in Serum Alanine Aminotransferase From Baseline at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>All-patients-randomised set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Logarithm Scale in Serum Alanine Aminotransferase From Baseline at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>All-patients-randomised set</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">678</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Nalmefene hydrochloride 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nalmefene hydrochloride 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalmefene hydrochloride</intervention_name>
    <description>As-needed; tablets, orally</description>
    <arm_group_label>Nalmefene hydrochloride 10 mg</arm_group_label>
    <arm_group_label>Nalmefene hydrochloride 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>As-needed; tablets, orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese males and females aged 20 or above who have signed the informed consent form

          -  The patient has alcohol dependence, diagnosed according to Diagnostic and Statistical
             Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) and confirmed by
             Mini-international Neuropsychiatric Interview (M. I. N. I.)

          -  The patient has a drinking risk level of High or above (&gt; 60 g for men and &gt; 40 g for
             women) both at the Screening Visit and at the Randomization Visit .

        Exclusion Criteria:

          -  The patient with a current diagnosis or history of substance use disorders (except for
             alcohol, nicotine, and caffeine), according to DSM-IV-TR and confirmed by M. I. N. I.

          -  The patient has reported current use of, or has tested positive for, drugs of abuse
             (opiates, methadone, cocaine, amphetamines, barbiturates) at the screening test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osamu Sato</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chubu</name>
      <address>
        <city>Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido</name>
      <address>
        <city>Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanto</name>
      <address>
        <city>Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki</name>
      <address>
        <city>Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyusyu</name>
      <address>
        <city>Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku</name>
      <address>
        <city>Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyugoku</name>
      <address>
        <city>Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>February 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2015</study_first_posted>
  <results_first_submitted>August 30, 2019</results_first_submitted>
  <results_first_submitted_qc>September 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 30, 2019</results_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nalmefene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Safety analysis set, which included all randomized patients who received ≥1 dose of the study medication.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Nalmefene Hydrochloride 20 mg</title>
          <description>as-needed, tablets, orally, 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Nalmefene Hydrochloride 10 mg</title>
          <description>as-needed, tablets, orally, 24 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>as-needed, tablets, orally, 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="248"/>
                <participants group_id="P2" count="184"/>
                <participants group_id="P3" count="245"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="139"/>
                <participants group_id="P3" count="219"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nalmefene Hydrochloride 20 mg</title>
          <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
        </group>
        <group group_id="B2">
          <title>Nalmefene Hydrochloride 10 mg</title>
          <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo: As-needed; tablets, orally</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="242"/>
            <count group_id="B2" value="180"/>
            <count group_id="B3" value="244"/>
            <count group_id="B4" value="666"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="217"/>
                    <measurement group_id="B4" value="589"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.9" spread="12.2"/>
                    <measurement group_id="B2" value="49.2" spread="11.9"/>
                    <measurement group_id="B3" value="48.1" spread="11.4"/>
                    <measurement group_id="B4" value="48.7" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="208"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="154"/>
                    <measurement group_id="B4" value="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="242"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="244"/>
                    <measurement group_id="B4" value="666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heavy Drinking Days (HDDs)</title>
          <description>The number of HDDs was defined as the number of days per month [days/month] with alcohol consumption of &gt; 60 g for males and &gt; 40 g for females.</description>
          <units>days/month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.64" spread="6.37"/>
                    <measurement group_id="B2" value="23.49" spread="6.07"/>
                    <measurement group_id="B3" value="22.97" spread="6.44"/>
                    <measurement group_id="B4" value="22.99" spread="6.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Alcohol Consumption (TAC)</title>
          <description>TAC was defined as mean alcohol consumption per day [g/day] over a 1-month period.</description>
          <units>g/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93.07" spread="37.45"/>
                    <measurement group_id="B2" value="95.93" spread="41.10"/>
                    <measurement group_id="B3" value="95.08" spread="48.70"/>
                    <measurement group_id="B4" value="94.58" spread="42.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Drinking Risk Level (DRL)</title>
          <description>DRL was defined by the World Health Organization based on average volume of alcohol consumption per Day.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Low</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Medium</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High</title>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="127"/>
                    <measurement group_id="B4" value="355"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very high</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impression – Severity of Illness (CGI-S) score</title>
          <description>The CGI-S scale was used by clinicians when assessing their global impression of a patient’s current clinical condition. The investigator or subinvestigator used his/her clinical experience with this patient population to rate the severity of a subject’s clinical condition on a 7-point scale ranging from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.38" spread="1.06"/>
                    <measurement group_id="B2" value="3.48" spread="1.15"/>
                    <measurement group_id="B3" value="3.45" spread="1.09"/>
                    <measurement group_id="B4" value="3.43" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum gamma-glutamyltransferase (γ-GT)</title>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.7" spread="105.4"/>
                    <measurement group_id="B2" value="80.7" spread="103.8"/>
                    <measurement group_id="B3" value="70.7" spread="78.7"/>
                    <measurement group_id="B4" value="78.5" spread="96.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum alanine aminotransferase (ALT)</title>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.3" spread="14.2"/>
                    <measurement group_id="B2" value="24.5" spread="14.9"/>
                    <measurement group_id="B3" value="23.3" spread="14.8"/>
                    <measurement group_id="B4" value="24.0" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Number of Heavy Drinking Days (HDDs) From Baseline at Week 12</title>
        <description>The number of HDDs is defined as the number of days per month [days/month] with alcohol consumption of &gt; 60 g for males and &gt; 40 g for females</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nalmefene Hydrochloride 20 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Nalmefene Hydrochloride 10 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: As-needed; tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Number of Heavy Drinking Days (HDDs) From Baseline at Week 12</title>
          <description>The number of HDDs is defined as the number of days per month [days/month] with alcohol consumption of &gt; 60 g for males and &gt; 40 g for females</description>
          <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
          <units>days/month</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.25" spread="0.64"/>
                    <measurement group_id="O2" value="-12.09" spread="0.74"/>
                    <measurement group_id="O3" value="-7.91" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, baseline value, and baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used.</non_inferiority_desc>
            <p_value>0.0001</p_value>
            <p_value_desc>Efficacy of the doses (change from baseline in the number of HDDs vs placebo) was assessed using a closed testing procedure. The 20 mg dose was tested at a 5% level of significance and only if significant, the testing would proceed to the 10 mg dose.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.05</ci_lower_limit>
            <ci_upper_limit>-2.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, baseline value, and baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used.</non_inferiority_desc>
            <p_value>0.0001</p_value>
            <p_value_desc>Efficacy of the doses (change from baseline in the number of HDDs vs placebo) was assessed using a closed testing procedure. The 20 mg dose was tested at a 5% level of significance and only if significant, the testing would proceed to the 10 mg dose.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.05</ci_lower_limit>
            <ci_upper_limit>-2.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Number of Heavy Drinking Days (HDDs) From Baseline at Week 24</title>
        <time_frame>Week 24</time_frame>
        <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nalmefene Hydrochloride 20 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Nalmefene Hydrochloride 10 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: As-needed; tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Number of Heavy Drinking Days (HDDs) From Baseline at Week 24</title>
          <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
          <units>days/month</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.25" spread="0.66"/>
                    <measurement group_id="O2" value="-13.88" spread="0.77"/>
                    <measurement group_id="O3" value="-9.33" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, baseline value, and baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.69</ci_lower_limit>
            <ci_upper_limit>-2.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, baseline value, and baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.46</ci_lower_limit>
            <ci_upper_limit>-2.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Alcohol Consumption (TAC) From Baseline at Week 12</title>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nalmefene Hydrochloride 20 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Nalmefene Hydrochloride 10 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: As-needed; tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Alcohol Consumption (TAC) From Baseline at Week 12</title>
          <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
          <units>g/day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.90" spread="2.01"/>
                    <measurement group_id="O2" value="-45.36" spread="2.32"/>
                    <measurement group_id="O3" value="-32.43" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in total alcohol consumption (TAC) from baseline at Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, baseline value, and baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.81</ci_lower_limit>
            <ci_upper_limit>-7.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, baseline value, and baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.72</ci_lower_limit>
            <ci_upper_limit>-7.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Alcohol Consumption (TAC) From Baseline at Week 24</title>
        <time_frame>Week 24</time_frame>
        <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nalmefene Hydrochloride 20 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Nalmefene Hydrochloride 10 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: As-needed; tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Alcohol Consumption (TAC) From Baseline at Week 24</title>
          <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
          <units>g/day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.43" spread="2.13"/>
                    <measurement group_id="O2" value="-49.55" spread="2.45"/>
                    <measurement group_id="O3" value="-38.28" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, baseline value, and baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used.</non_inferiority_desc>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.77</ci_lower_limit>
            <ci_upper_limit>-5.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, baseline value, and baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used.</non_inferiority_desc>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.37</ci_lower_limit>
            <ci_upper_limit>-5.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Shift Drinking Risk Level (RSDRL) at Week 12</title>
        <description>Proportion of patients with a downward shift in drinking risk level of two categories or more</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nalmefene Hydrochloride 20 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Nalmefene Hydrochloride 10 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: As-needed; tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Response Shift Drinking Risk Level (RSDRL) at Week 12</title>
          <description>Proportion of patients with a downward shift in drinking risk level of two categories or more</description>
          <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3"/>
                    <measurement group_id="O2" value="35.7"/>
                    <measurement group_id="O3" value="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Cochran-Mantel-Haenszel test, stratified by sex and baseline DRL</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>22.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.6</ci_lower_limit>
            <ci_upper_limit>30.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Cochran-Mantel-Haenszel test, stratified by sex and baseline DRL</non_inferiority_desc>
            <p_value>0.0007</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>15.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.5</ci_lower_limit>
            <ci_upper_limit>25.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Shift Drinking Risk Level (RSDRL) at Week 24</title>
        <description>Proportion of patients with a downward shift in drinking risk level of two categories or more</description>
        <time_frame>Week 24</time_frame>
        <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nalmefene Hydrochloride 20 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Nalmefene Hydrochloride 10 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: As-needed; tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Response Shift Drinking Risk Level (RSDRL) at Week 24</title>
          <description>Proportion of patients with a downward shift in drinking risk level of two categories or more</description>
          <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="47.5"/>
                    <measurement group_id="O3" value="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Cochran-Mantel-Haenszel test, stratified by sex and baseline DRL</non_inferiority_desc>
            <p_value>0.0002</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>18.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.8</ci_lower_limit>
            <ci_upper_limit>27.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Cochran-Mantel-Haenszel test, stratified by sex and baseline DRL</non_inferiority_desc>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>20.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.4</ci_lower_limit>
            <ci_upper_limit>30.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Low Drinking Risk Level (RLDRL) at Week 12</title>
        <description>Proportion of patients with low or lower drinking risk level</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nalmefene Hydrochloride 20 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Nalmefene Hydrochloride 10 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: As-needed; tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Response Low Drinking Risk Level (RLDRL) at Week 12</title>
          <description>Proportion of patients with low or lower drinking risk level</description>
          <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6"/>
                    <measurement group_id="O2" value="25.3"/>
                    <measurement group_id="O3" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Cochran-Mantel-Haenszel test, stratified by sex and baseline DRL</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>17.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.5</ci_lower_limit>
            <ci_upper_limit>25.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Cochran-Mantel-Haenszel test, stratified by sex and baseline DRL</non_inferiority_desc>
            <p_value>0.0002</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>14.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.4</ci_lower_limit>
            <ci_upper_limit>22.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Low Drinking Risk Level (RLDRL) at Week 24</title>
        <description>Proportion of patients with low or lower drinking risk level</description>
        <time_frame>Week 24</time_frame>
        <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nalmefene Hydrochloride 20 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Nalmefene Hydrochloride 10 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: As-needed; tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Response Low Drinking Risk Level (RLDRL) at Week 24</title>
          <description>Proportion of patients with low or lower drinking risk level</description>
          <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6"/>
                    <measurement group_id="O2" value="32.6"/>
                    <measurement group_id="O3" value="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Cochran-Mantel-Haenszel test, stratified by sex and baseline DRL</non_inferiority_desc>
            <p_value>0.0079</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>11.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.9</ci_lower_limit>
            <ci_upper_limit>19.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Cochran-Mantel-Haenszel test, stratified by sex and baseline DRL</non_inferiority_desc>
            <p_value>0.0010</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>14.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.8</ci_lower_limit>
            <ci_upper_limit>23.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>70% TAC Responder Rate at Week 12</title>
        <description>Proportion of patients with a 70% decrease in TAC</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nalmefene Hydrochloride 20 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Nalmefene Hydrochloride 10 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: As-needed; tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>70% TAC Responder Rate at Week 12</title>
          <description>Proportion of patients with a 70% decrease in TAC</description>
          <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0"/>
                    <measurement group_id="O2" value="19.5"/>
                    <measurement group_id="O3" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Cochran-Mantel-Haenszel test, stratified by sex and baseline value</non_inferiority_desc>
            <p_value>0.0022</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>9.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.5</ci_lower_limit>
            <ci_upper_limit>16.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Cochran-Mantel-Haenszel test, stratified by sex and baseline value</non_inferiority_desc>
            <p_value>0.0016</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>11.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.8</ci_lower_limit>
            <ci_upper_limit>18.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>70% TAC Responder Rate at Week 24</title>
        <description>Proportion of patients with a 70% decrease in TAC</description>
        <time_frame>Week 24</time_frame>
        <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nalmefene Hydrochloride 20 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Nalmefene Hydrochloride 10 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: As-needed; tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>70% TAC Responder Rate at Week 24</title>
          <description>Proportion of patients with a 70% decrease in TAC</description>
          <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8"/>
                    <measurement group_id="O2" value="23.4"/>
                    <measurement group_id="O3" value="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Cochran-Mantel-Haenszel test, stratified by sex and baseline value</non_inferiority_desc>
            <p_value>0.0003</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>13.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.2</ci_lower_limit>
            <ci_upper_limit>20.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Cochran-Mantel-Haenszel test, stratified by sex and baseline value</non_inferiority_desc>
            <p_value>0.0013</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>12.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.6</ci_lower_limit>
            <ci_upper_limit>21.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HDD Responder Rate at Week 12</title>
        <description>Proportion of patients with ≤4 HDDs</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nalmefene Hydrochloride 20 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Nalmefene Hydrochloride 10 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: As-needed; tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>HDD Responder Rate at Week 12</title>
          <description>Proportion of patients with ≤4 HDDs</description>
          <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0"/>
                    <measurement group_id="O2" value="36.4"/>
                    <measurement group_id="O3" value="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Cochran-Mantel-Haenszel test, stratified by sex and baseline value</non_inferiority_desc>
            <p_value>0.0002</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>15.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.1</ci_lower_limit>
            <ci_upper_limit>23.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Cochran-Mantel-Haenszel test, stratified by sex and baseline value</non_inferiority_desc>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>17.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.9</ci_lower_limit>
            <ci_upper_limit>26.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HDD Responder Rate at Week 24</title>
        <description>Proportion of patients with ≤4 HDDs</description>
        <time_frame>Week 24</time_frame>
        <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nalmefene Hydrochloride 20 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Nalmefene Hydrochloride 10 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: As-needed; tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>HDD Responder Rate at Week 24</title>
          <description>Proportion of patients with ≤4 HDDs</description>
          <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9"/>
                    <measurement group_id="O2" value="44.0"/>
                    <measurement group_id="O3" value="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Cochran-Mantel-Haenszel test, stratified by sex and baseline value</non_inferiority_desc>
            <p_value>0.0724</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>8.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>16.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Cochran-Mantel-Haenszel test, stratified by sex and baseline value</non_inferiority_desc>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>19.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.9</ci_lower_limit>
            <ci_upper_limit>29.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CGI-S From Baseline at Week 12</title>
        <description>The CGI-S scale was used by clinicians when assessing their global impression of a patient's current clinical condition. The investigator or subinvestigator used his/her clinical experience with this patient population to rate the severity of a subject's clinical condition on a 7-point scale ranging from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients).</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nalmefene Hydrochloride 20 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Nalmefene Hydrochloride 10 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: As-needed; tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CGI-S From Baseline at Week 12</title>
          <description>The CGI-S scale was used by clinicians when assessing their global impression of a patient's current clinical condition. The investigator or subinvestigator used his/her clinical experience with this patient population to rate the severity of a subject's clinical condition on a 7-point scale ranging from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients).</description>
          <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.05"/>
                    <measurement group_id="O2" value="-0.63" spread="0.06"/>
                    <measurement group_id="O3" value="-0.34" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, baseline value, and baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used.</non_inferiority_desc>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>-0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, baseline value, and baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used.</non_inferiority_desc>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CGI-S From Baseline at Week 24</title>
        <description>The CGI-S scale was used by clinicians when assessing their global impression of a patient's current clinical condition. The investigator or subinvestigator used his/her clinical experience with this patient population to rate the severity of a subject's clinical condition on a 7-point scale ranging from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients).</description>
        <time_frame>Week 24</time_frame>
        <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nalmefene Hydrochloride 20 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Nalmefene Hydrochloride 10 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: As-needed; tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CGI-S From Baseline at Week 24</title>
          <description>The CGI-S scale was used by clinicians when assessing their global impression of a patient's current clinical condition. The investigator or subinvestigator used his/her clinical experience with this patient population to rate the severity of a subject's clinical condition on a 7-point scale ranging from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients).</description>
          <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.06"/>
                    <measurement group_id="O2" value="-0.77" spread="0.07"/>
                    <measurement group_id="O3" value="-0.41" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, baseline value, and baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, baseline value, and baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CGI-I From Baseline at Week 12</title>
        <description>The CGI-I scale is used to assess a patient's improvement (or worsening). The investigator or subinvestigator assesses a subject's condition relative to baseline on a 7-point scale ranging from 1 (Very much improved) to 7 (Very much worse).</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nalmefene Hydrochloride 20 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Nalmefene Hydrochloride 10 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: As-needed; tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CGI-I From Baseline at Week 12</title>
          <description>The CGI-I scale is used to assess a patient's improvement (or worsening). The investigator or subinvestigator assesses a subject's condition relative to baseline on a 7-point scale ranging from 1 (Very much improved) to 7 (Very much worse).</description>
          <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" spread="0.07"/>
                    <measurement group_id="O2" value="2.65" spread="0.08"/>
                    <measurement group_id="O3" value="3.13" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, baseline value, and baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used. Baseline CGI-S value was used as baseline value in MMRM.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, baseline value, and baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used. Baseline CGI-S value was used as baseline value in MMRM.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.67</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CGI-I From Baseline at Week 24</title>
        <description>The CGI-I scale was used to assess a patient's improvement (or worsening). The investigator or subinvestigator assesses a subject's condition relative to baseline on a 7-point scale ranging from 1 (Very much improved) to 7 (Very much worse).</description>
        <time_frame>Week 24</time_frame>
        <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nalmefene Hydrochloride 20 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Nalmefene Hydrochloride 10 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: As-needed; tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CGI-I From Baseline at Week 24</title>
          <description>The CGI-I scale was used to assess a patient's improvement (or worsening). The investigator or subinvestigator assesses a subject's condition relative to baseline on a 7-point scale ranging from 1 (Very much improved) to 7 (Very much worse).</description>
          <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" spread="0.07"/>
                    <measurement group_id="O2" value="2.44" spread="0.09"/>
                    <measurement group_id="O3" value="2.99" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, baseline value, and baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used. Baseline CGI-S value was used as baseline value in MMRM.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.70</ci_lower_limit>
            <ci_upper_limit>-0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, baseline value, and baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used. Baseline CGI-S value was used as baseline value in MMRM.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Logarithm Scale in Serum γ-glutamyltransferase From Baseline at Week 12</title>
        <description>All-patients-randomised set</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nalmefene Hydrochloride 20 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Nalmefene Hydrochloride 10 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: As-needed; tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Logarithm Scale in Serum γ-glutamyltransferase From Baseline at Week 12</title>
          <description>All-patients-randomised set</description>
          <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
          <units>IU/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.666" spread="0.027"/>
                    <measurement group_id="O2" value="3.702" spread="0.031"/>
                    <measurement group_id="O3" value="3.858" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, logarithm scale baseline value, and logarithm scale baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.192</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.262</ci_lower_limit>
            <ci_upper_limit>-0.121</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, logarithm scale baseline value, and logarithm scale baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used.</non_inferiority_desc>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.156</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.232</ci_lower_limit>
            <ci_upper_limit>-0.080</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Logarithm Scale in Serum γ-glutamyltransferase From Baseline at Week 24</title>
        <description>All-patients-randomised set</description>
        <time_frame>Week 24</time_frame>
        <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nalmefene Hydrochloride 20 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Nalmefene Hydrochloride 10 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: As-needed; tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Logarithm Scale in Serum γ-glutamyltransferase From Baseline at Week 24</title>
          <description>All-patients-randomised set</description>
          <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
          <units>IU/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.663" spread="0.031"/>
                    <measurement group_id="O2" value="3.692" spread="0.035"/>
                    <measurement group_id="O3" value="3.831" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, logarithm scale baseline value, and logarithm scale baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.168</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.248</ci_lower_limit>
            <ci_upper_limit>-0.088</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, logarithm scale baseline value, and logarithm scale baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used.</non_inferiority_desc>
            <p_value>0.0017</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.139</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.044</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.226</ci_lower_limit>
            <ci_upper_limit>-0.052</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Logarithm Scale in Serum Alanine Aminotransferase From Baseline at Week 12</title>
        <description>All-patients-randomised set</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nalmefene Hydrochloride 20 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Nalmefene Hydrochloride 10 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: As-needed; tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Logarithm Scale in Serum Alanine Aminotransferase From Baseline at Week 12</title>
          <description>All-patients-randomised set</description>
          <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
          <units>IU/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.968" spread="0.023"/>
                    <measurement group_id="O2" value="2.988" spread="0.027"/>
                    <measurement group_id="O3" value="3.038" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, logarithm scale baseline value, and logarithm scale baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used.</non_inferiority_desc>
            <p_value>0.0234</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.070</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.031</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.130</ci_lower_limit>
            <ci_upper_limit>-0.009</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, logarithm scale baseline value, and logarithm scale baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.1374</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.049</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.033</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.115</ci_lower_limit>
            <ci_upper_limit>0.016</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Logarithm Scale in Serum Alanine Aminotransferase From Baseline at Week 24</title>
        <description>All-patients-randomised set</description>
        <time_frame>Week 24</time_frame>
        <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nalmefene Hydrochloride 20 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Nalmefene Hydrochloride 10 mg</title>
            <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: As-needed; tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Logarithm Scale in Serum Alanine Aminotransferase From Baseline at Week 24</title>
          <description>All-patients-randomised set</description>
          <population>Full analysis set, which included all patients who had data on the number of HDDs at baseline and at ≥1 time point after initiation of the study drug.</population>
          <units>IU/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.971" spread="0.023"/>
                    <measurement group_id="O2" value="2.987" spread="0.027"/>
                    <measurement group_id="O3" value="3.036" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, logarithm scale baseline value, and logarithm scale baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used.</non_inferiority_desc>
            <p_value>0.0348</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.066</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.031</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.127</ci_lower_limit>
            <ci_upper_limit>-0.005</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point, treatment-by-time point interaction, logarithm scale baseline value, and logarithm scale baseline value-by-time point interaction with an unstructured variance-covariance matrix structure was used.</non_inferiority_desc>
            <p_value>0.1444</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.049</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.034</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.116</ci_lower_limit>
            <ci_upper_limit>0.017</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24-week treatment period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nalmefene Hydrochloride 20 mg</title>
          <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
        </group>
        <group group_id="E2">
          <title>Nalmefene Hydrochloride 10 mg</title>
          <description>Nalmefene hydrochloride: As-needed; tablets, orally</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo: As-needed; tablets, orally</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Ver. 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Ver. 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="175" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="127" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="91" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>Otsuka Pharmaceutical Co., Ltd.</organization>
      <email>CL_OPCJ_RDA_Team@otsuka.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

